Cohort study to assess geographical variation in cholangiocarcinoma treatment in England

Figure 1 Percentage of cholangiocarcinoma patients treated with potentially curative surgery in each Cancer Alliance in England, 2014-2017. A: Unadjusted; B: Adjusted. Adjustment for: age, gender, income deprivation quintile, Charlson comorbidity index, underlying liver disease at diagnosis, diagnosis year, tumour morphology, tumour sub-type, and routes to diagnosis. Inner dashed line = two standard deviations difference from average. Outer dashed line = three standard deviations difference from average.

Figure 2 Percentage of cholangiocarcinoma patients treated with systemic therapy amongst those who did not receive surgery in each Cancer Alliance in England, 2014-2017. A: Unadjusted; B: Adjusted. Adjustment for: age, gender, income deprivation quintile, Charlson comorbidity index, underlying liver disease at diagnosis, diagnosis year, tumour morphology, tumour sub-type, and routes to diagnosis. Inner dashed line = two standard deviations difference from average. Outer dashed line = three standard deviations difference from average.

Figure 3 Percentage of cholangiocarcinoma patients treated with stent insertion amongst those who did not receive surgery in each Cancer Alliance in England, 2014-2017. A: Unadjusted; B: Adjusted. Adjustment for: age, gender, income deprivation quintile, Charlson comorbidity index, underlying liver disease at diagnosis, diagnosis year, tumour morphology, tumour sub-type, and routes to diagnosis. Inner dashed line = two standard deviations difference from average. Outer dashed line = three standard deviations difference from average.